SCYNEXIS, Inc.(SCYX)Earnings, Financials & Key RatiosSCYNEXIS, Inc. (SCYX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to maintain consistent commercial revenue, highlighted by the 2026Q1 revenue drop to zero, suggests significant and potentially insurmountable market adoption hurdles.
SCYNEXIS, Inc. (SCYX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
SCYNEXIS, Inc. (SCYX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.42vs $0.10-320.0% | —vs $77,000 |
| Q2 2026 | Mar 4, 2026 | $0.25vs $0.13+97.3% | $19Mvs $8M+130.2% |
| Q4 2025 | Nov 5, 2025 | $0.17vs $0.21+19.0% | $334,000vs $8M-95.9% |
| Q3 2025 | Aug 13, 2025 | $0.14vs $0.23+39.1% | $1Mvs $154,000+785.7% |
Recent stock market news and headlines for SCYNEXIS, Inc. (SCYX)
JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator.
Key metrics vs top competitors for SCYNEXIS, Inc. (SCYX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.61 | $28.99M | -3.39 | 449.95% | -41.79% | -16.48% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $221.38 | $6.96B | -8.28 | -94.52% | — | -43.74% | — | |
| $12.58 | $718.13M | -7.49 | — | -17567.99% | -53.17% | — | |
| $136.36 | $169.3B | 20.11 | 2.39% | 30.99% | 42.33% | — |
SCYNEXIS, Inc. (SCYX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SCYNEXIS, Inc. (SCYX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 29, 2026·SEC
May 22, 2026·SEC
Apr 20, 2026·SEC
Get notified when SCYX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SCYNEXIS, Inc. (SCYX) stock FAQ — growth, dividends, profitability & financials explained
SCYNEXIS, Inc. (SCYX) reported $20.3M in revenue for fiscal year 2025. This represents a 21% increase from $16.8M in 2012.
SCYNEXIS, Inc. (SCYX) grew revenue by 449.9% over the past year. This is strong growth.
SCYNEXIS, Inc. (SCYX) reported a net loss of $24.5M for fiscal year 2025.
SCYNEXIS, Inc. (SCYX) has a return on equity (ROE) of -16.5%. Negative ROE indicates the company is unprofitable.
SCYNEXIS, Inc. (SCYX) had negative free cash flow of $5.9M in fiscal year 2025, likely due to heavy capital investments.
